DiaMedica Therapeutics, Inc. (DMAC)
8.18
+0.16
(+2.00%)
USD |
NASDAQ |
Nov 20, 10:35
DiaMedica Therapeutics Free Cash Flow : -33.68M for Sept. 30, 2026
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| September 30, 2026 | -33.68M |
| June 30, 2026 | -31.67M |
| March 31, 2026 | -31.49M |
| December 31, 2025 | -29.56M |
| September 30, 2025 | -27.69M |
| June 30, 2025 | -25.55M |
| March 31, 2025 | -22.13M |
| December 31, 2024 | -21.63M |
| September 30, 2024 | -19.18M |
| June 30, 2024 | -19.52M |
| March 31, 2024 | -20.15M |
| December 31, 2023 | -18.58M |
| September 30, 2023 | -17.48M |
| June 30, 2023 | -14.92M |
| March 31, 2023 | -12.32M |
| December 31, 2022 | -11.12M |
| September 30, 2022 | -11.42M |
| June 30, 2022 | -12.06M |
| March 31, 2022 | -11.77M |
| December 31, 2021 | -12.21M |
| September 30, 2021 | -12.67M |
| June 30, 2021 | -12.25M |
| March 31, 2021 | -10.84M |
| December 31, 2020 | -9.503M |
| September 30, 2020 | -8.114M |
| Date | Value |
|---|---|
| June 30, 2020 | -6.934M |
| March 31, 2020 | -8.997M |
| December 31, 2019 | -9.151M |
| September 30, 2019 | |
| June 30, 2019 | |
| March 31, 2019 | |
| December 31, 2018 | |
| September 30, 2018 | -4.802M |
| June 30, 2018 | -3.815M |
| March 31, 2018 | -4.21M |
| December 31, 2017 | -4.066M |
| September 30, 2017 | |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | |
| September 30, 2016 | -2.131M |
| June 30, 2016 | -1.312M |
| March 31, 2016 | -1.472M |
| December 31, 2015 | -1.425M |
| September 30, 2015 | -1.163M |
| June 30, 2015 | -1.777M |
| March 31, 2015 | -3.060M |
| December 31, 2014 | -3.871M |
| September 30, 2014 | -4.358M |
| June 30, 2014 | -4.636M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -283.94M |
| Nektar Therapeutics | -257.48M |
| Fortress Biotech, Inc. | 120.19M |
| ACADIA Pharmaceuticals, Inc. | 81.99M |
| Alnylam Pharmaceuticals, Inc. | 752.13M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -8.641M |
| Cash from Investing (Quarterly) | 10.25M |
| Cash from Financing (Quarterly) | 0.1097M |
| Free Cash Flow Per Share (Quarterly) | -0.1604 |
| Free Cash Flow to Equity (Quarterly) | -8.623M |
| Free Cash Flow to Firm (Quarterly) | -8.651M |
| Free Cash Flow Yield | -7.63% |